Januvia Dose Adjustment For Renal Insufficiencies Not Needed For Galvus
Merck's type 2 diabetes treatment Januvia may necessitate dose adjustment for patients with renal insufficiencies; a precaution not necessary for Novartis' competing dipeptidyl peptidase IV inhibitor Galvus, the Swiss firm maintained